TY -的A2 Pichler罗伯特•AU -高桥Rina AU - Sakamoto, Kazuhiro AU - Sugimoto, Kiichi AU - Motegi, Shunsuke AU - Tsukamoto, Ryoichi AU - Ichikawa, Ryosuke AU - Okazawa, Yu AU - Aoki, Jun AU - Ishiyama, Shun AU - Takahashi, Makoto AU - Kojima, Yutaka AU - Okuzawa, Atsushi AU - Tomiki, Yuichi AU - Matsuoka, Joe PY - 2019 DA - 2019/12/16 TI - Significance of Serum p53 Antibody as a Tumor Marker in Colorectal Cancer SP - 2721876 VL - 2019 AB - Objective. We examined serum anti-p53 antibodies (S-p53Ab) in colorectal cancer. Specifically, we retrospectively investigated the use of S-p53Ab as a prognostic marker after surgery for colorectal cancer. Materials and Methods. The levels of S-p53Ab, carcinoembryonic antigen (CEA), and carbohydrate antigen 19-9 (CA19-9) were measured in 160 colorectal cancer patients who underwent surgical treatment. The rate of postoperative change (RPC) in the S-p53Ab titer was calculated as [subsequent antibody titer-lowest titer]/lowest titer. Results. A relationship between recurrence and RPC in the S-p53Ab titer was not observed in patients who tested negative for S-p53Ab preoperatively. In addition, no patients, who tested negative for S-p53Ab preoperatively, tested positive for S-p53Ab at the follow-up after surgery. Of the patients who tested positive for S-p53Ab preoperatively, those recurrences had a significantly higher RPC compared with those who did not ( p < 0.001 )。 Conclusions. Although S-p53Ab is not a significant tumor marker in patients who test negative preoperatively, increases in the S-p53Ab titer should be continuously monitored and measured in patients who are positive for this antibody preoperatively, regardless of whether they later test negative. SN - 0278-0240 UR - https://doi.org/10.1155/2019/2721876 DO - 10.1155/2019/2721876 JF - Disease Markers PB - Hindawi KW - ER -